Published in Women's Health Weekly, October 12th, 2000
"As a majority of ovarian cancer patients will ultimately develop recurrent disease, there is an urgent need for alternative or additional approaches in the treatment of this cancer," wrote A.H. Klimp and colleagues, University of Groningen. "The antitumor effect of intraperitoneally (i.p.) administered cisplatin, liposomal muramyltripeptide phosphatidylethanolamine (L-MTP-PE), and granulocyte-macrophage colony-stimulating factor (GM-CSF) were investigated using an intraperitoneally growing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly